eNOS overexpression exacerbates vascular closure in the obliterative phase of OIR and increases angiogenic drive in the subsequent proliferative stage

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 11, 2012, Pages 6833-6850

  Edgar, Kevin ^a   Gardiner, Thomas A ^a   van Haperen, Rien ^b   de Crom, Rini ^b   McDonald, Denise M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GREEN FLUORESCENT PROTEIN; NITRIC OXIDE SYNTHASE; NITRITE; OXYGEN; REACTIVE OXYGEN METABOLITE; TETRAHYDROBIOPTERIN; VASCULOTROPIN; NOS3 PROTEIN, MOUSE;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPEROXIA; IMMUNOLOCALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA ISCHEMIA; RETINOPATHY; VASCULAR RING; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL PROLIFERATION; COMPARATIVE STUDY; DISEASE MODEL; ENZYMOLOGY; FEMALE; MALE; PATHOLOGY; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE III; RETINAL NEOVASCULARIZATION; RETINAL VESSELS;

EID: 84871853431     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9797     Document Type: Article

References (50)

1. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994; 118:445-450.
2. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331:1480-1487.
3. Pierce E, Avery R, Foley E, Aiello L, Smith L. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92:905-909.
4. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995;15: 4738-4747.
5. Ozaki H, Seo M-S, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol. 2000;156:697-707.
6. Saint-Geniez M, Maharaj ASR, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on Muller cells and photoreceptors. PLoS ONE. 2008;3: e3554.
7. Sennlaub F, Courtois Y, Goureau O. Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. J Clin Invest. 2001;107: 717-725.
8. Gardiner TA, Gibson DS, de Gooyer TE, de la Cruz VF, McDonald DM, Stitt AW. Inhibition of tumor necrosis factor-α improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. Am J Pathol. 2005;166:637-644.
9. Papapetropoulos A, García-Cardeña G, Madri J, Sessa W. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest. 1997;100:3131-3139.
10. Ziche M, Morbidelli L, Choudhuri R, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest. 1997;99:2625-2634.
11. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399: 601-605.
12. Murohara T, Witzenbichler B, Spyridopoulos I, et al. Role of endothelial nitric oxide synthase in endothelial cell migration. Arterioscler Thromb Vasc Biol. 1999;19:1156-1161.
13. Brooks SE, Gu X, Samuel S, et al. Reduced severity of oxygeninduced retinopathy in eNOS-deficient mice. Invest Ophthalmol Vis Sci. 2001;42:222-228.
14. Ando A, Yang A, Mori K, et al. Nitric oxide is proangiogenic in the retina and choroid. J Cell Physiol. 2002;191:116-124.
15. Amano K, Matsubara H, Iba O, et al. Enhancement of ischemiainduced angiogenesis by eNOS overexpression. Hypertension. 2003;41:156-162.
16. Namba T, Koike H, Murakami K, et al. Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation. 2003;108:2250-2257.
17. Stone J. Development of retinal vasculature is mediated by hypoxia-induced endothelial growth factor expression by neuroglia. J Neurosci. 1995;15:4738-4747.
18. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003;161:1163-1177.
19. Xia Y, Tsai AL, Berka V, Zweier JL. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem. 1998;273:25804-25808.
20. Hardy P, Beauchamp M, Sennlaub F, et al. New insights into the retinal circulation: inflammatory lipid mediators in ischemic retinopathy. Prostaglandins Leukot Essent Fatty Acids. 2005; 72:301-325.
21. Saito Y, Uppal A, Byfield G, Budd S, Hartnett ME. Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model. Invest Ophthalmol Vis Sci. 2008;49:1591-1598.
22. Uno K, Merges CA, Grebe R, Lutty GA, Prow TW. Hyperoxia inhibits several critical aspects of vascular development. Dev Dyn. 2007;236:981-990.
23. Kermorvant-Duchemin E, Sennlaub F, Sirinyan M, et al. Transarachidonic acids generated during nitrative stress induce a thrombospondin-1-dependent microvascular degeneration. Nat Med. 2005;11:1339-1345.
24. Laursen JB, Somers M, Kurz S, et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation. 2001;103:1282-1288.
25. Ozaki M, Kawashima S, Yamashita T, et al. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest. 2002; 110:331-340.
26. van Haperen R, de Waard M, van Deel E, et al. Reduction of blood pressure, plasma cholesterol, and atherosclerosis by elevated endothelial nitric oxide. J Biol Chem. 2002;277: 48803-48807.
27. van Haperen R, Cheng C, Mees BME, et al. Functional expression of endothelial nitric oxide synthase fused to green fluorescent protein in transgenic mice. Am J Pathol. 2003; 163:1677-1686.
28. Cheng C, van Haperen R, de Waard M, et al. Shear stress affects the intracellular distribution of eNOS: direct demonstration by a novel in vivo technique. Blood. 2005;106:3691-3698.
29. Smith L, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35: 101-111.
30. Stevenson L, Matesanz N, Colhoun L, et al. Reduced nitrooxidative stress and neural cell death suggests a protective role for microglial cells in TNF-/-mice in ischemic retinopathy. Invest Ophthalmol Vis Sc. 2010;51:3291-3299.
31. Matesanz N, Park G, McAllister H, et al. Docosahexaenoic acid improves the nitroso-redox balance and reduces VEGF mediated angiogenic signaling in microvascular endothelial cells. Invest Ophthalmol Vis Sci. 2010;51:6815-6825.
32. Suchting S, Heal P, Tahtis K, Stewart LM, Bicknell R. Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration. FASEB J. 2004;19:121-123.
33. Garcia-Cardena G, Martasek P, Masters BS, et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the NOS caveolin binding domain in vivo. J Biol Chem. 1997;272:25437-25440.
34. Michel JB, Feron O, Sacks D, Michel T. Reciprocal regulation of endothelial nitric-oxide synthase by Ca2+-calmodulin and caveolin. J Biol Chem. 1997;272:15583-15586.
35. Garcia-Cardena G, Oh P, Liu JW, Schnitzer JE, Sessa WC. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation-implications for nitric oxide signaling. Proc Natl Acad Sci U S A. 1996;93:6448-6453.
36. Ju H, Zou R, Venema VJ, Venema RC. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J Biol Chem. 1997;272:18522-18525.
37. Fulton D, Gratton J-P, McCabe TJ, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399:597-601.
38. McDonald D, Alp N, Channon K. Functional comparison of the endothelial nitric oxide synthase Glu298Asp polymorphic variants in human endothelial cells. Pharmacogenetics. 2004; 14:831-839.
39. Chan-Ling T, Gock B, Stone J. The effect of oxygen on vasoformative cell division. Evidence that "physiological hypoxia" is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol Vis Sci. 1995;36:1201-1214.
40. Fukumura D, Gohongi T, Kadambi A, et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A. 2001;98:2604-2609.
41. Kashiwagi S, Izumi Y, Gohongi T, et al. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J Clin Invest. 2005;115: 1816-1827.
42. Parsons-Wingerter P, Chandrasekharan UM, McKay TL, et al. A VEGF165-induced phenotypic switch from increased vessel density to increased vessel diameter and increased endothelial NOS activity. Microvasc Res. 2006;72:91-100.
43. Ushio-Fukai M, Tang Y, Fukai T, et al. Novel role of gp91phoxcontaining NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res. 2002;91: 1160-1167.
44. Al-Shabrawey M, Bartoli M, El-Remessy AB, et al. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am J Pathol. 2005;167:599-607.
45. El-Remessy AB, Al-Shabrawey M, Platt DH, et al. Peroxynitrite mediates VEGF's angiogenic signal and function via a nitrationindependent mechanism in endothelial cells. Am J Pathol. 2007;21:2528-2539.
46. Ebrahimian TG, Heymes C, You D, et al. NADPH oxidasederived overproduction of reactive oxygen species impairs postischemic neovascularization in mice with type 1 diabetes. Am J Pathol. 2006;169:719-728.
47. Li Calzi S, Purich DL, Chang KH, et al. Carbon monoxide and nitric oxide mediate cytoskeletal reorganization in microvascular cells via vasodilator-stimulated phosphoprotein phosphorylation. Diabetes. 2008;57:2488-2494.
48. Haddad P, Dussault S, Groleau J, et al. Nox2-containing NADPH oxidase deficiency confers protection from hindlimb ischemia in conditions of increased oxidative stress. Arterioscler Thromb Vasc Biol. 2009;29:1522-1528.
49. Bendall JK, Alp NJ, Warrick N, et al. Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and eNOS coupling in vivo: insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS overexpression. Circ Res. 2005;97: 864-871.
50. Takaya T, Hirata K-I, Yamashita T, et al. A specific role for eNOS-derived reactive oxygen species in atherosclerosis progression. Arterioscler Thromb Vasc Biol. 2007;27:1632-1637.